| Shuxian Qu,Jianing Qiu,Yidan Zhang,Yongming Liu,Zhendong Zheng. Application of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for the prevention of neutropenia in triple negative breast cancer patients older than 65 years during adjuvant chemotherapy. Oncol Transl Med, 2019, 5: 218-222. |
| RhG-CSF应用预防65岁以上高复发风险乳腺癌术后密集化疗相关性粒细胞减少症的研究 |
| Application of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) for the prevention of neutropenia in triple negative breast cancer patients older than 65 years during adjuvant chemotherapy |
| Received:April 12, 2019 Revised:November 22, 2019 |
| DOI：10.1007/s10330-019-0350-0 |
| 中文关键词: 老年；乳腺癌；粒细胞减少症；聚乙二醇化重组人粒细胞集落刺激因子 |
| 英文关键词: elderly; breast cancer; neutropenia; pegylated recombinant human granulocyte colonystimulating factor |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Shuxian Qu | Department of Oncology, General Hospital of Shenyang Military Region, Shenyang | qushuxian2010@163.com | | Jianing Qiu | Department of Oncology, The General Hospital of the Northern Theater of the Chinese people's Liberation Army, Shenyang 110000, China | | | Yidan Zhang | Department of Oncology of traditional Chinese and Western Medicine, Northeast international hospital, Shenyang 110000, China | | | Yongming Liu | Department of Oncology, The General Hospital of the Northern Theater of the Chinese people's Liberation Army, Shenyang 110000, China | | | Zhendong Zheng* | Department of Oncology, The General Hospital of the Northern Theater of the Chinese people's Liberation Army, Shenyang 110000, China | |
|
| Hits: 8507 |
| Download times: 9630 |
| 中文摘要: |
| 目的：比较聚乙二醇化重组人粒细胞集落刺激因子( PEG-rhG-CSF) 和重组人粒细胞集落刺激因子( rhG-CSF)一级预防老年高危乳腺癌病人术后辅助化疗相关性中性粒细胞减少症的临床疗效和安全性。方法：选取2017年5月-2018年10月于沈阳军区总医院肿瘤科住院行辅助化疗且年龄大于65岁的乳腺癌术后患者，共45例。化疗方案选择CE序贯T密集方案辅助化疗。45例分为两组，其中治疗组25例患者应用聚乙二醇化重组人粒细胞刺激因子预防治疗，对照组20例患者化疗期间未进行PEG-rhG-CSF预防治疗，仅给予rhG-CSF对症治疗。治疗组在化疗结束后24～48 h内给予聚乙二醇化重组人粒细胞集落刺激因子，预防给药方式为皮下注射，剂量6 mg/次，每个化疗周期给药1次[1] 。对照组重组人粒细胞集落刺激因( rhG-CSF)，化疗结束48后，100μg皮下注射，1次/d，d1-7[2]，用药剂量可随白细胞减少程度的加重而逐级递增用量[3]。观察两组白细胞减少、中性粒细胞数减少,中性粒细胞减少性发热发生率，不良反应发生情况，结果：治疗组中性粒细胞数减少和中性粒细胞减少性发热发生率均较对照组明显降低，但比较差异无统计学意义（P>0.05）；不良反应发生数治疗组较对照组低，但两组均无统计学意义（P>0.05）。结论：应用聚乙二醇化重组人粒细胞集落刺激因子可有效预防老年乳腺癌化疗后粒细胞减少，能有效控制乳腺癌化疗后粒细胞抑制的发生，减少感染机会，发热、骨痛等副反应发生率低，耐受性较好，患者的依从性高，能保障化疗的顺利进行。 |
| 英文摘要: |
| Objective The aim of this study was to compare the efficacy and safety of pegylated recombinant
human granulocyte colony-stimulating factor (PEG-rhG-CSF) and recombinant human granulocyte colonystimulating factor (rhG-CSF) for the prevention of neutropenia in elderly breast cancer patients during
adjuvant chemotherapy.
Methods A total of 45 oncology inpatients with breast cancer, who received adjuvant chemotherapy
and were older than 65 years from May 2017 to October 2018 in the General Hospital of the Northern
Theater of the Chinese people’s Liberation Army, were included. Epirubivin Cyclophoshamide-Docetaxel
(EC-T) sequential adjuvant chemotherapy was chosen. Forty-five patients were randomly divided into two
groups; 25 patients in the treatment group were treated with PEG-rhG-CSF and 20 patients in the control
group were not treated with PEG-rhG-CSF, but only rhG-CSF. The experimental group was treated with
the PEG-rhG-CSF at the end of chemotherapy for 24–48 h, with a 6 mg subcutaneous injection once
per chemotherapy cycle. In the control group, rhG-CSF was administered after 48 h of chemotherapy,
with a 100 μg subcutaneous injection, 1/d, d 1–7. The dosage could be increased step by step with the
exacerbation of neutropenia. The primary aims of this study was to discover the incidence of leukopenia,
neutropenia, neutrophilic fever, and adverse reactions in the two groups.
Results The incidence of neutropenia, neutrophilic fever and adverse reactions decreased in the
treatment group compared to the control group, but no significant difference existed between two groups
(P > 0.05). Patients in treatment group had a lower, but not statistically significant, incidence of adverse
reactions (P > 0.05).
Conclusion Applying PEG-rhG-CSF could be effective in preventing neutropenia in elderly patients with
postoperative adjuvant chemotherapy to treat breast cancer. It may effectively control the occurrence of
neutropenia after chemotherapy and reduce the chance of infection. The incidence of side effects, such
as fever and bone pain, was low. The adverse drug reactions were well tolerated by patients, which could
ensure the smooth progress of chemotherapy. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|